Transparency Life Sciences (TLS), a NYC-based developer of digital drug development clinical services, completed a $5.0m Series A financing.
The round was led by venture investor New Ventures III with participation from existing private investors. In conjunction with the funding, New Ventures’ Richard Warburg, PhD and Harry Glorikian will join the TLS Board of Directors.
The company will use the new funds to expand its technology platform and clinical operations infrastructure, and drive commercialization of its integrated digital approach to clinical drug development.
Led by Tomasz Sablinski, MD, PhD, co-founder and CEO, Transparency Life Science combines crowdsourcing and mobile health technology to advance drug candidates through clinical trials with efficiency and patient and regulatory relevance. The use of digital technology allows the company to reduce or eliminate reliance on physical study sites and limit the geographic scope of enrollment.
Platform elements include:
– Transparency Protocol Crowdsourcing™, an online, crowdsourced approach to clinical study protocols co-designed by patients and physicians that are relevant to real-world medical needs;
– Transparency Virtual Trials™, a virtual trial hub integrating telemedicine, mobile health and cloud technologies to conduct trials; and
– Transparency Personalized Digityping™, a form of patient digital phenotyping that uses mobile health technology to identify and stratify the right participants for each clinical trial.